07:17 AM EDT, 09/15/2025 (MT Newswires) -- Ocugen ( OCGN ) said Monday it has signed an exclusive licensing agreement with Kwangdong Pharmaceutical for the rights to commercialize its experimental gene therapy, OCU400, for the treatment of retinitis pigmentosa in South Korea.

Under the deal, Ocugen ( OCGN ) said it will receive up to $7.5 million in upfront and near-term milestone payments. It added that the company would also be entitled to sales milestones of $1.5 million for every $15 million in Korean sales.

Ocugen ( OCGN ) said it will also earn a 25% royalty on net sales and will supply the commercial product to Kwangdong.

The therapy is currently in phase 3 trials, with a US marketing application filing targeted for 2026, the company said, adding that Kwangdong plans to use its clinical and regulatory data in its own submission for Korean approval.